 WATERTOWN, Mass., Oct. 4, 2021 PRNewswire -- Lyra Therapeutics, Inc. Nasdaq: LYRA, a clinical-stage therapeutics company leveraging its proprietary XTreoTM platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat ENT passages and other diseased tissues, announced that new, positive LYR-210 data from the LANTERN 6-month post-treatment evaluation and recently completed pharmacokinetic study, were the subject of two oral presentations at the 67th Annual Meeting of the American Rhinologic Society ARS on October 1-2. 